Podcast Feature · Hypermobility Research

Folate, Methylation, and the Hypermobile Body
What Dr. Courseault Discussed on the Lateral Think Podcast.

An hour-long Australian podcast conversation in 2023 — and the research it surfaces — has become one of the more important reference points for hypermobility care at our Beverly Hills clinic.

In August 2023, Dr. Jacques Courseault sat down with the team at Lateral Think — The Melbourne Athletic Development Podcast for a 58-minute conversation that has quietly become one of the more important reference points in the hypermobility community. The subject was a publication Dr. Courseault had just released exploring the connection between dietary micronutrient intake — particularly folate — and the symptom burden of hypermobility syndromes.

Two years later, that research continues to shape how we treat hypermobile patients at The Fascia Institute of LA in Beverly Hills. This post unpacks the core idea, why it matters for Los Angeles patients living with chronic joint pain, fatigue, and “bendy” symptoms — and how to act on it in practice.

The Core Idea — Folate-Dependent Hypermobility

For decades, hypermobility was treated almost exclusively as a structural problem: lax ligaments, soft tissue laxity, “loose joints.” Treatment plans focused on strengthening, bracing, and physical therapy. Those interventions still matter — but they only address part of the picture.

Dr. Courseault’s research proposes that a substantial subset of hypermobile patients — many of whom have been diagnosed with hypermobile Ehlers-Danlos syndrome (hEDS) or Hypermobility Spectrum Disorder (HSD) — are operating with a measurable functional folate deficiency. Not because they are not eating folate, but because their methylation cycle cannot convert it efficiently into the usable form (5-methyltetrahydrofolate, or 5-MTHF).

The downstream consequence is what we now call folate-dependent hypermobility: a connective-tissue dysfunction driven not by a primary collagen defect, but by impaired one-carbon metabolism affecting collagen cross-linking, mast cell stability, neurotransmitter regulation, and tissue repair. This is a paradigm shift. It means that for the right patient, a methylation-aware nutritional protocol can do what stretching, bracing, and pain management never quite did on their own.

Why Methylation Matters for Hypermobility Patients

Methylation is the cellular process by which your body adds a methyl group (a small carbon-hydrogen unit) to DNA, neurotransmitters, hormones, and structural proteins. It depends on a small set of micronutrients — folate (B9), B12, B6, choline, and methionine being the most relevant — and on the genetic machinery that converts those nutrients into their active forms.

The most well-studied genetic variant in this pathway is MTHFR C677T. Patients carrying one or two copies of this polymorphism have reduced ability to produce active 5-MTHF. Antoniades and colleagues (2009) documented the functional importance of this polymorphism for one-carbon metabolism — a finding directly relevant to why some hypermobile patients respond dramatically to methylated folate supplementation while others do not.

Other variants in MTRR, COMT, and the broader methylation cycle compound the picture. The result, in clinical terms, is that two patients with “the same” hypermobility diagnosis can have very different underlying biochemistry — and therefore very different optimal treatment plans.

What This Means for Hypermobility Patients in Los Angeles

Los Angeles has more access to specialty care than almost any other city in the country — and yet hypermobile patients here routinely describe the same experience: rotating through orthopedics, rheumatology, neurology, and gastroenterology without ever being treated as a single system. The folate-dependent hypermobility framework changes the conversation in three concrete ways.

How We Operationalize This at FIT LA

Every hypermobility patient at The Fascia Institute of LA has the option of beginning with Genomics Performance Screening (GPS) — our personalized testing platform that measures methylation status, B-vitamin and glutathione capacity, inflammatory markers, and the genetic variants that govern how your body processes folate. The data tells us whether folate-dependent hypermobility is part of your picture — and if so, what a clinically appropriate supplementation protocol looks like for you specifically.

That information then feeds directly into the rest of your care plan. Physical therapy, ultrasound-guided injection medicine, and the multi-modal recovery work we offer through programs like AURA all perform better when the underlying biochemistry is corrected. The methylation work is not a substitute for the structural work — it is the layer underneath it that determines how well the structural work holds.

“The Lateral Think conversation is one of the more accessible introductions to this research — Dr. Courseault explains it the way he explains it to patients, not the way the journal article reads.”